• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

    47.58 -0.31 (-0.65%)
    Streaming Delayed Price Updated: 10:41 AM EDT, Jul 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Structure Therapeutics Inc. - American Depositary Shares

    < Previous 1 2 Next >
    News headline image
    Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Participation in Upcoming Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
    Via AB Newswire
    News headline image
    Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Can Roche Challenge Lilly and Novo in the Weight Loss Market?
    One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
    Via MarketBeat
    News headline image
    Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
    Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
    Via MarketBeat
    News headline image
    Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Appoints Angus C. Russell to Board of Directors
    Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry 
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.